Back to Search
Start Over
Acceleration of interstitial lung disease induced by raltitrexed.
- Source :
-
Journal of Oncology Pharmacy Practice . Jul2020, Vol. 26 Issue 5, p1241-1243. 3p. - Publication Year :
- 2020
-
Abstract
- Introduction: Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities. Case report: We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma. Management and outcome: Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests. Discussion: The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10781552
- Volume :
- 26
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Journal of Oncology Pharmacy Practice
- Publication Type :
- Academic Journal
- Accession number :
- 144422092
- Full Text :
- https://doi.org/10.1177/1078155219887213